Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torben Biester

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|October 18, 2021
The automated pancreas: A review of technologies and clinical practiceTorben Biester, Martin Tauschmann, Agata Chobot, et al.
Pharmacological Research|August 5, 2023
New therapies towards a better glycemic control in youths with type 1 diabetesRoque Cardona-Hernandez, Klemen Dôvc, Torben Biester, et al.
Diabetes Technology & Therapeutics|January 19, 2017
"Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes PatientsTorben Biester, Olga Kordonouri, Martin Holder, et al.
Diabetes, Obesity & Metabolism|April 19, 2017
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetesTorben Biester, Baerbel Aschemeier, Maryam Fath, et al.
Journal of Diabetes Science and Technology|November 21, 2014
Lipoatrophy in children with type 1 diabetes: an increasing incidence?Olga Kordonouri, Torben Biester, Kerstin Schnell, et al.
British Journal of Clinical Pharmacology|May 12, 2019
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitusDavid Busse, Weifeng Tang, Markus Scheerer, et al.
Endocrine Connections|July 6, 2023
Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesityLaura Hasse, Dagmar Jamiolkowski, Felix Reschke, et al.
Pediatric Diabetes|January 20, 2016
Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetesTorben Biester, Thomas Danne, Sarah Bläsig, et al.
Pediatric Diabetes|April 20, 2020
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetesTorben Biester, Thekla von dem Berge, Line Quist Bendtsen, et al.
Diabetes, Obesity & Metabolism|April 2, 2025
Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and EuropeCari Berget, S Francesca Annan, Torben Biester, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|October 18, 2021
The automated pancreas: A review of technologies and clinical practiceTorben Biester, Martin Tauschmann, Agata Chobot, et al.
Pharmacological Research|August 5, 2023
New therapies towards a better glycemic control in youths with type 1 diabetesRoque Cardona-Hernandez, Klemen Dôvc, Torben Biester, et al.
Diabetes Technology & Therapeutics|January 19, 2017
"Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes PatientsTorben Biester, Olga Kordonouri, Martin Holder, et al.
Diabetes, Obesity & Metabolism|April 19, 2017
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetesTorben Biester, Baerbel Aschemeier, Maryam Fath, et al.
Journal of Diabetes Science and Technology|November 21, 2014
Lipoatrophy in children with type 1 diabetes: an increasing incidence?Olga Kordonouri, Torben Biester, Kerstin Schnell, et al.
British Journal of Clinical Pharmacology|May 12, 2019
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitusDavid Busse, Weifeng Tang, Markus Scheerer, et al.
Endocrine Connections|July 6, 2023
Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesityLaura Hasse, Dagmar Jamiolkowski, Felix Reschke, et al.
Pediatric Diabetes|January 20, 2016
Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetesTorben Biester, Thomas Danne, Sarah Bläsig, et al.
Pediatric Diabetes|April 20, 2020
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetesTorben Biester, Thekla von dem Berge, Line Quist Bendtsen, et al.
Diabetes, Obesity & Metabolism|April 2, 2025
Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and EuropeCari Berget, S Francesca Annan, Torben Biester, et al.
Pageof 6